Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
![VGD](https://www.ohe.org/wp-content/uploads/2021/02/VGD_0-150x150.png)
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.